These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16152713)

  • 1. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity.
    Walker UA; Venhoff N
    Antivir Ther; 2005; 10 Suppl 2():M117-23. PubMed ID: 16152713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells.
    Walker UA; Venhoff N; Koch EC; Olschewski M; Schneider J; Setzer B
    Antivir Ther; 2003 Oct; 8(5):463-70. PubMed ID: 14640394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions.
    Walker UA; Auclair M; Lebrecht D; Kornprobst M; Capeau J; Caron M
    Antivir Ther; 2006; 11(1):25-34. PubMed ID: 16518957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy.
    Lewis W
    Antivir Ther; 2005; 10 Suppl 2():M13-27. PubMed ID: 16152703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy.
    Côté HC
    Antivir Ther; 2005; 10 Suppl 2():M3-11. PubMed ID: 16152702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes.
    Igoudjil A; Massart J; Begriche K; Descatoire V; Robin MA; Fromenty B
    Toxicol In Vitro; 2008 Jun; 22(4):887-98. PubMed ID: 18299183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on mitochondrial toxicity: where are we now?
    Walker UA
    J HIV Ther; 2003 May; 8(2):32-5. PubMed ID: 12838162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
    Nolan D; Hammond E; James I; McKinnon E; Mallal S
    Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A brief overview of mechanisms of mitochondrial toxicity from NRTIs.
    Kohler JJ; Lewis W
    Environ Mol Mutagen; 2007; 48(3-4):166-72. PubMed ID: 16758472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.
    Moyle G
    Clin Ther; 2000 Aug; 22(8):911-36; discussion 898. PubMed ID: 10972629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.
    Venhoff N; Setzer B; Melkaoui K; Walker UA
    Antivir Ther; 2007; 12(7):1075-85. PubMed ID: 18018766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
    Sievers M; Walker UA; Sevastianova K; Setzer B; Wågsäter D; Eriksson P; Yki-Järvinen H; Sutinen J
    J Infect Dis; 2009 Jul; 200(2):252-62. PubMed ID: 19519254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.
    Kakuda TN
    Clin Ther; 2000 Jun; 22(6):685-708. PubMed ID: 10929917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
    De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
    Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice.
    Lebrecht D; Deveaud C; Beauvoit B; Bonnet J; Kirschner J; Walker UA
    Arthritis Rheum; 2008 Jan; 58(1):318-26. PubMed ID: 18163507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid analysis of mitochondrial DNA depletion by fluorescence in situ hybridization and immunocytochemistry: potential strategies for HIV therapeutic monitoring.
    Janes MS; Hanson BJ; Hill DM; Buller GM; Agnew JY; Sherwood SW; Cox WG; Yamagata K; Capaldi RA
    J Histochem Cytochem; 2004 Aug; 52(8):1011-8. PubMed ID: 15258176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes.
    Setzer B; Schlesier M; Thomas AK; Walker UA
    Antivir Ther; 2005; 10(2):327-34. PubMed ID: 15865227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.
    Walker UA; Bäuerle J; Laguno M; Murillas J; Mauss S; Schmutz G; Setzer B; Miquel R; Gatell JM; Mallolas J
    Hepatology; 2004 Feb; 39(2):311-7. PubMed ID: 14767983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria.
    Moyle G
    Antivir Ther; 2005; 10 Suppl 2():M47-52. PubMed ID: 16152705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic stavudine exposure induces hepatic mitochondrial toxicity in adult Erythrocebus patas monkeys.
    Gerschenson M; Nguyen VT; St Claire MC; Harbaugh SW; Harbaugh JW; Proia LA; Poirier MC
    J Hum Virol; 2001; 4(6):335-42. PubMed ID: 12082400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.